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aBsTRacT
INTRODUCTION: In Denmark, age-related macular degener-
ation (AMD) is the most common cause of blindness. To 
better understand current and future challenges, we esti-
mated and projected the annual number of patients with 
neovascular AMD and geographic atrophy in Denmark from 
2016 to 2060.
METHODS: Detailed age- and gender-stratified prevalence 
estimates of neovascular AMD and geographic atrophy in a 
Scandinavian population were identified and applied to age- 
and gender-stratified population numbers provided by Stat-
istics Denmark. Prevalence estimates were calculated for 
each year from 2016 to 2060. Future forecasts were pro-
vided by Statistics Denmark and based on calculations by 
the Danish Institute for Economic Modelling and Forecast-
ing.
RESULTS: We estimated that there are currently ~30,000 
patients with neovascular AMD and ~21,000 patients with 
geographic atrophy in Denmark. The majority of these pa-
tients are persons aged ≥ 85 years. For neovascular AMD, 
the number of patients will grow to ~33,000 in 2020, 
~58,000 in 2040 and ~72,000 in 2060. For geographic  
atrophy, the number of patients will grow to ~23,000 in 
2020, ~41,000 in 2040, and ~50,000 in 2060.
CONCLUSIONS: We expect a steady growth in the preva-
lence of neovascular AMD and geographic atrophy in Den-
mark due to an ageing population. These numbers empha-
sise the importance of disease prevention, careful planning 
of health service activities and continuing research.
FUNDING: none.
TRIAL REGISTRATION: not relevant.
 
Age-related macular degeneration (AMD) is a degenera-
tive disease of the central retina [1]. In Denmark, one 
out of three persons above 60 years of age have early 
signs of the disease defined as the presence of small  
deposits of cellular debris under the retina (drusen) [2]. 
Drusen formation is linked to an inefficiency of the re-
tina and its supporting epithelium to handle the con-
stant exposure to reactive oxygen species [1]. This is the 
result of an age-related decline in cellular function [3], 
genetic composition [1] and environmental exposure 
[1]. Overall, ageing is the single most important factor 
for the development of early AMD and for progression 
to the late stages of the disease [1], which comprises 
two substantially different phenotypes (Figure 1). 
One phenotype – neovascular AMD – is character-
ised by formation of new vessels in the choroid (capil-
laries under the retina) which protrude through Bruch’s 
membrane (basal membrane of the retina) and into the 
retina [1]. This neovascularisation is caused by a com-
plex immunological interplay wherein secretion of vas-
cular endothelial growth factor (VEGF) is the most im-
portant driving force [4, 5], which can be counteracted 
clinically by intravitreal injections with VEGF inhibitors 
[6, 7]. If left untreated or if the treatment is unrespon-
sive, fibrosis starts developing, which marks the end-
stage of neovascular AMD where vision is lost perma-
nently [1]. 
Another phenotype of late AMD – geographic  
atrophy – is characterised by a neurodegenerative pro-
cess wherein retinal nerve cells and supporting tissue 
undergo cellular death in clearly demarcated areas [1]. 
There is currently no approved medical treatment; how-
ever, this might change in near future since phase 2- 
results of a monoclonal antibody targeted complement 
factor D, Lampalizumab (Genentech, CA, USA), was re-
cently published with results suggesting a 20% reduction 
in lesion area progression [8].
Both neovascular AMD and geographic atrophy sig-
nificantly impact the quality of life of the patients [7, 9]. 
Patients develop rapid visual loss upon progression to 
neovascular AMD [1]. Patients typically complain of  
sudden worsening of central vision that is described as 
straight lines becoming wavy (metamorphopsia), blurred 
vision or an area with no vision (scotoma). The visual 
loss is typically slower in patients with geographic  
atrophy [1], and the visual experience can be character-
ised as blurred vision that gradually takes the form of a 
scotoma. Visual rehabilitation does exist and is focused 
on using the remaining vision to sustain visual function 
as much as possible. In Denmark, this task is performed 
by dedicated institutes around the country (in Danish: 
“synscentraler”). 
Diagnosis, treatment and rehabilitation of AMD 
proves a significant challenge in the publicly funded 
Danish healthcare system. The large number of patients 
underlines the need for careful design of health the ser-
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vices [10, 11] and constitutes a significant economic bur-
den as VEGF inhibitors generated costs of approximately 
400 m DKK in 2016 in Denmark alone according to the 
Danish Health Data Authority. 
In Denmark, an ongoing demographic shift is ex-
pected to significantly increase the number of elderly 
people. In this paper, our aim was to estimate the 
Danish prevalence of subtypes of late AMD – neovascu-
lar AMD and geographic atrophy – and their projected 
prevalence until 2060 to provide a basis for discussions, 
decisions and planning.
mEThOds 
Population numbers for denmark and projections  
until 2060
Statistics Denmark is the central authority on societal 
statistics in Denmark. Every year, Statistics Denmark 
compiles data on current population, immigration, emi-
gration, livebirths and deaths, which are then provided 
to the Danish Institute for Economic Modelling and Fore-
casting (DREAM), which is an independent semi-govern-
mental institution that provides analyses and forecasting 
relating to the Danish economy [12]. Statistics Denmark 
and DREAM model the data based on assumptions re-
garding migration, fertility and mortality [12]. The as-
sumptions are based on historical experience [12]. 
Based on the final model, one population projection is 
made available to the public, which may be further 
stratified by different variables such as age and gender 
[13]. Its assumptions on population primo and popula-
tion increase (calculated from immigration, emigration, 
livebirths, and deaths) are also available to the public 
[12].
Prevalence estimates of neovascular age-related  
macular degeneration and geographic atrophy
Several studies have characterised the prevalence of 
AMD in Nordic countries. The Copenhagen City Eye 
Study was a population-based investigation of visual 
acuity and eye diseases conducted in a subsample of 
participants from the Copenhagen City Heart Study [14]. 
Here, the investigators looked at various aspects of late 
AMD, but the prevalence of neovascular AMD and geog-
raphic atrophy were not published as age- and gender-
stratified prevalence data [14]. The Tromsø Eye study in-
cluded a subgroup from the 6th Tromsø Study, where 
2,539 participants aged 65-87 years had fundus photo-
graphs taken [15]. This study determined the prevalence 
and characteristics of different subtypes of AMD, includ-
ing geographic atrophy and neovascular AMD [15]. In a 
larger study, the population-based cohort Age Gene/ 
Environment Susceptibility (AGES) Reykjavik Study re-
cruited 5,330 individuals aged 66-91 years [16]. Since 
this latter study was the largest with available detailed 
age- and gender-stratified characterisation of the preva-
lence of neovascular AMD and geographic atrophy in a 
Nordic Caucasian population [16], we decided to use its 
estimates for the present study.
data analysis
TaBlE 1
Population of elderly people in Denmark in 2016 and estimated number of patients with neovascular 
age-related macular degeneration (AMD) using the prevalence estimates of the Age Gene/Environment 
Susceptibility Reykjavik Study.
neovascular amd geographic atrophy
age group, yrs Total population, n % n % n
Females
66-69    141,834   0.6      851 0.3      426
70-74    151,845   1.3   1,974 0.7   1,063
75-79    104,872   3.1   3,251 1.9   1,993
80-84      72,159   6.0   4,330 5.8   4,185
≥ 85      79,025 11.3   8,930 6.4   5,058
Males
66-69    136,122   0.5      681 0.0          0
70-74    140,598   0.6      844 0.2      281
75-79      89,001   1.5   1,335 1.9   1,691
80-84      53,210   6.3   3,352 4.4   2,341
≥ 85      39,364 11.4   4,487 9.0   3,543
Total 1,008,030   3.0 30,034 2.0 20,580
FigURE 1
a. Retinal photograph of a left eye with neovascular age-related macular 
degeneration. B. Retinal angiography is used for a detailed examination, 
diagnosis and activity measurement of the choroidal neovascularisation. 
Shown here in a locational-matched yellow-framed image, early-phase 
fluorescein-based retinal angiography clearly reveals the neovascular  
activity. c. Retinal photograph of a right eye with geographic atrophy.  
d. Retinal auto-fluorescence is used for a detailed examination, diagnosis 
and activity measurement of the geographic atrophy. Shown here in a lo-
cational-matched blue-framed image, lack of auto-fluorescence confirms 
degeneration of the retinal pigment epithelium-photoreceptor complex. 
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For each year from 2016 to 2060, we used the age- and 
gender-stratified population counts and estimates from 
Statistics Denmark [13] and estimated the age- and gen-
der-specific numbers of patients with neovascular AMD 
and geographic atrophy using the prevalence estimates 
from the AGES study [16]. All calculations were made in 
Excel 2013 (Microsoft, Redmont, WA, USA) and figures 
were prepared in Prism 7 (GraphPad Software, La Jolla, 
CA, USA).
Trial registration: not relevant.
REsUlTs
Population numbers are presented in Table 1 together 
with prevalence estimates. We estimate that there are 
currently ~30,000 patients with neovascular AMD and 
~21,000 patients with geographic atrophy in Denmark. 
The majority of these patients are aged ≥ 85 years.
The estimated numbers of patients with neovascu-
lar AMD are presented in Figure 2. We expect a steady 
growth in prevalence, mainly due to an increase in the 
group of people aged ≥ 85 years. This will lead to the  
following forecast of patients with neovascular AMD: 
~33,000 in year 2020, ~48,000 in year 2030, ~58,000 in 
year 2040, ~68,000 in year 2050 and ~72,000 in year 
2060.
The estimated number of patients with geographic 
atrophy are presented in Figure 3. We expect a steady 
growth in the prevalence of geographic atrophy due to 
an increase in the group of people aged ≥ 85 years.  
This leads to the following forecast of patients with  
geographic atrophy: ~23,000 in year 2020, ~34,000 in 
year 2030, ~41,000 in year 2040, ~48,000 in year 2050 
and ~50,000 in year 2060.
discUssiOn
We find that the expected number of patients with any 
late AMD in Danes aged ≥ 65 years is approximately 
51,000, which we project will increase to approximately 
122,000 patients in 2060. This increase is mainly the re-
sult of an increase in the number of people aged ≥ 85 
years. 
Ageing is the most important risk factor for progres-
sion from early AMD to late AMD [1]. Other important 
risk factors are family history and lifestyle factors such 
as physical inactivity, obesity and cigarette smoking [1]. 
The Age-Related Eye Disease Studies (AREDS) investi-
gated the effects of various antioxidant vitamins and 
minerals in patients with early AMD in a randomised 
controlled manner. Based on the positive findings from 
the latest AREDS2 study, the following oral supplement 
is recommended per day: vitamin C (500 mg), vitamin E 
(400 IU), zink (80 mg), copper (2 mg), lutein (10 mg) and 
zeaxanthin (2 mg) [17]. Beyond this treatment, studies 
suggest that the strongest effect of risk reduction is ob-
tainable through smoking cessation and increased phys-
ical activity [1, 2]. Smoking increases the risk of progres-
sion by 30% and smoking cessation may lower the risk to 
that of non-smokers [1, 2]. Being moderately or highly 
physically active can decrease the risk of progression by 
30-50% when compared with physically inactive people 
[2].
FigURE 3
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FigURE 2
Projected number of patients with neovascular age-related macular de-


























Total ≥ 85 years 80-84 years
75-79 years 70-74 years 66-69 years
0
 4   da n i s h m E d i c a l J O U R n a l Dan Med J 64/11   November 2017
Lindekleiv & Erke estimated the number of patients 
with late AMD in Scandinavia in 2013 without distin-
guishing the subtypes of neovascular AMD and geog-
raphic atrophy [18]. Their estimate of approximately 
47,000 patients with any late AMD in Denmark in 2013 
are in line with the findings of our study. The Danish 
Council for the Use of Expensive Hospital Medicines in 
Denmark (Rådet for Anvendelse af Dyr Sygehusmedicin) 
estimated that the number of patients with neovascular 
AMD who are in treatment was 13,000-14,000 in their 
recommendations published in December 2016 [19]. It  
is expected that one out of every three will discontinue 
treatment after a year and that some patients present 
with untreatable eyes [19]. Høeg et al mapped the epi-
demiology of adult visual impairment in Denmark and 
found that 50% of visually impaired patients with neo-
vascular AMD were in treatment with VEGF inhibitors 
[20]. These numbers confirm that the total number of 
patients with neovascular AMD in Denmark may be 
around 30,000, which is in line with the results reported 
in the present paper. Taken together, these numbers 
demonstrate that AMD is a relatively common disease in 
Denmark and that we expect an increase in the demand 
of retinal services. Research is needed into how best to 
organise such services, and even small improvements 
towards a higher efficiency (speed of treatment and let-
ting nurses perform injections) or a lower risk of compli-
cations (use of operating rooms and protocols for pre-
parations) are welcome to facilitate the necessary 
adaptation to the increasing demand [10, 11]. 
Important study limitations should be highlighted. 
First, prevalence estimates are based on a representa-
tive Scandinavian population (the Icelandic population), 
which can only be considered an approximation. Second, 
population projections are based on qualified guesses 
and likely models on important demographic variables: 
life expectancy, immigration, emigration, livebirths and 
deaths. The future number of patients thus depends on 
the model’s ability to predict correctly. Third, future de-
velopments in risk reduction of progression to neovascu-
lar AMD or geographic atrophy may decrease the preva-
lence of these late stages of the disease. 
cOnclUsiOns
We estimate the number of patients with neovascular 
AMD to be approximately 30,000 and the number of pa-
tients with geographic atrophy to be approximately 
21,000. We expect a steady growth in these numbers in 
the future, mainly due to an increase in the group of 
persons aged ≥ 85 years. In year 2060, we expect the 
number of patients with any late AMD to be approxi-
mately 122,000. Attention should be given to disease 
prevention, careful planning of health services and con-
tinuing research.
cORREsPOndEncE: Yousif Subhi. E-mail: ysubhi@gmail.com
accEPTEd: 27 September 2017
cOnFlicTs OF inTEREsT: Disclosure forms provided by the authors are 
available with the full text of this article at www.danmedj.dk
liTERaTURE
1. Lim LS, Mitchell P, Seddon JM et al. Age-related macular degeneration. 
Lancet 2012;379:1728-38.
2. Subhi Y, Munch IC, Singh A et al. Physical activity benefits patients with 
age-related macular degeneration. Ugeskr Laeger 2015;177:1624-7.
3. Subhi Y, Forshaw T, Sørensen TL. Macular thickness and volume in the 
elderly: a systematic review. Ageing Res Rev 2016;29:42-9.
4. Subhi Y, Lykke Sørensen T. New neovascular age-related macular degen-
eration is associated with systemic leucocyte activity. Acta Ophthalmol 
2017;95:472-80.
5. Singh A, Subhi Y, Krogh Nielsen M et al. Systemic frequencies of T helper 1 
and T helper 17 cells in patients with age-related macular degeneration:  
a case-control study. Sci Rep 2017;7:605.
6. Subhi Y, Henningsen GØ, Larsen CT et al. Foveal morphology affects self-
perceived visual function and treatment response in neovascular age-
related macular degeneration: a cohort study. PLoS One 2014;9:e91227.
7. Subhi Y, Sørensen TL. Neovascular age-related macular degeneration in 
the very old (≥90 years): epidemiology, adherence to treatment, and 
comparison of efficacy. J Ophthalmol 2017;2017:7194927.
8. Yaspan BL, Williams DF, Holz FG et al. Targeting factor D of the alternative 
complement pathway reduces geographic atrophy progression secondary 
to age-related macular degeneration. Sci Transl Med 2017;9:eaaf1443.
9. Subhi Y, Sørensen TL. Physical activity patterns in patients with early and 
late age-related macular degeneration. Dan Med J 2016;63(11):A5303.
10. Subhi Y, Kjer B, Munch IC. Prefilled syringes for intravitreal injection reduce 
preparation time. Dan Med J 2016;63(4):A5214.
11. Rasul A, Subhi Y, Sørensen TL et al. Non-physician delivered intravitreal 
injection service is feasible and safe - a systematic review. Dan Med J 
2016;63(5):A5229.
12. Documentation of statistics. Population Projections for Denmark. www.
dst.dk/en/Statistik/dokumentation/documentationofstatistics/population-
projections-for-denmark (18 Sep 2017).
13. Population and population projections. Population projections.  
www.dst.dk/en/Statistik/emner/befolkning-og-valg/befolkning-og-
befolkningsfremskrivning/befolkningsfremskrivning  (18 Sep 2017).
14. Buch H, Vinding T, La Cour M et al. Prevalence and causes of visual 
impairment and blindness among 9980 Scandinavian adults: the 
Copenhagen City Eye Study. Ophthalmology 2004;111:53-61.
15. Erke MG, Bertelsen G, Peto T et al. Prevalence of age-related macular 
degeneration in elderly Caucasians: the Tromsø Eye Study. Ophthalmology 
2012;119:1737-43.
16. Jonasson F, Arnarsson A, Eiríksdottir G et al. Prevalence of age-related 
macular degeneration in old persons: Age, Gene/environment 
Susceptibility Reykjavik Study. Ophthalmology 2011;118:825-30.
17. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and 
omega-3 fatty acids for age-related macular degeneration: the Age-
Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 
2013;309:2005-15.
18. Lindekleiv H, Erke MG. Projected prevalence of age-related macular 
degeneration in Scandinavia 2012-2040. Acta Ophthalmol 2013;91:307-11.
19. Rådet for Anvendelse af Dyr Sygehusmedicin. Baggrundsnotat for 
behandling af våd aldersrelateret maculadegeneration. Version 2.0, 
December 2016. www.regioner.dk/media/4157/vamd-bgn-20-dec-16.pdf 
(18 Sep 2017).
20. Høeg TB, Ellervik C, Buch H et al. Danish Rural Eye Study: Epidemiology of 
adult visual impairment. Ophthalmic Epidemiol 2016;23:53-62. 
